anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1. Granulate for the preparation of fast-disintegrating, and fast-dissolving compositions, containing an active ingredient, having a solubility in water of 1: > 10, in admixture with a water dispersible cellulose, which is a microcrystalline cellulose and sodium carboxymethyl cellulose, characterised in that the water dispersible cellulose is present in an amount of < 15 wt%, the percentage based on the weight of the active ingredient. 2. Granulate according to claim 1, characterised in that it contains 1-7.5 wt% of the water dispersible cellulose. 3. Granulate according to claim 1 or 2, characterised in that it contains 2-5 wt% of the water dispersible cellulose. 4. Granulate according to any one of claims 1-3, characterised in that the water dispersible cellulose contains 8,3-13,8 wt% of sodium carboxymethyl cellulose. 5. Granulate according to any one of claims 1-4, characterised in that it has been prepared by a conventional wet granulation technique. 6. Fast-disintegrating and fast-dissolving composition, containing at least one granulate according to any one of claims 1-5 in admixture with a first disintegrant and a second disintegrant, further pharmaceutically acceptable excipients and optionally a drug or a compound, enhancing the activity of the active ingredient incorporated in the granulate. 7. Composition according to claim 6, characterised in that one or more of the granulates according to any one of claims 1-5 are present in a total amount of  > 80 wt%, in admixture with 2-8 wt% of a first disintegrant and 2-8 wt% of a second disintegrant, the percentages based on the weight of the composition. 8. Composition according to claim 7, characterised in that the first disintegrant is microcrystalline cellulose, microfine cellulose or a mixture thereof and the second disintegrant is starch or a starch derivative, cross-linked polyvinylpyrrolidone or lowsubstituted hydroxypropyl cellulose. 9. Composition according to claim 7 or 8, characterised in that the first disintegrant and the second disintegrant are present in a ratio of 1:1.
PURPOSE:To obtain a new KO-8119 substance effective against drug-resistant Coccidium and useful as a therapeutic agent, etc., for treating coccidiomycosis, by culturing a microorganism which belongs to the genus Streptomyces and is capable of producing KO-8189 substance in a medium. CONSTITUTION:A microorganism [e.g. Streptomyces sp. KO-8119 (FERM P-13398)] which belongs to the genus Streptomyces and is capable of producing KO-8119 substance expressed by formula I (R is a group of formula II, formula III, etc.) is inoculated into a medium and cultured in a jar incubator at 27 deg.C for 3 day to afford a seed culture medium. Then, the seed culture medium is subjected to submerged culture at 27 deg.C for 3 day and pH of the cultured mixture is adjusted to 8.5 and the cultured mixture is extracted with ethyl acetate and the extracted liquid is concentrated and purified by silica gel chromatography and reverse phase high-performance liquid chromatography to provide the objective new KO-8119 substance expressed by formula I, effective against drug-resistant coccidium, especially coccidium having resistance to polyether-based compound.
BACKGROUND Endoscopic inguinal hernia repair has become the preferred technique currently. The use of mesh to facilitate a tension-free reinforcement has become the standard of care during endoscopic totally extraperitoneal (TEP), laparoscopic transabdominal pre-peritoneal, and open inguinal hernia repair. Although uncommon, late-developing mesh infections, defined as those occurring in the surgical site months or years after the procedure, can lead to severe complications. To achieve the best possible outcome for the patient, prompt imaging and a multidisciplinary approach to management, including complete surgical removal of the contaminated mesh and proper antibiotic therapy, are crucial. CASE REPORT A 39-year-old woman presented with a 1-month history of intermittent fever, progressive lower abdominal pain and fullness, and purulent discharge from the abdominal wall. Her medical history was significant for an endoscopic right TEP inguinal hernia repair performed 3 years earlier, which involved the use of an anatomic mesh and titanium screws. Physical examination and ultrasound findings revealed a large preperitoneal abscess with cutaneous fistulization, secondary to a deep-seated mesh infection. Pseudomonas aeruginosa was identified as the causative pathogen. She underwent a 2-step surgical procedure, including an initial fistulectomy followed by endoscopic abscess drainage and surgical excision of the infected mesh, combined with antimicrobial therapy, resulting in an excellent clinical response and complete resolution. This strategy also allowed for an effective assessment of the abdominal wall integrity. CONCLUSIONS This case underscores the importance of considering late-developing mesh infections in patients presenting with abdominal symptoms who have previously undergone TEP hernia repair, even years after the initial surgery.
The invention relates to a lipid emulsion with a low anisidine value, which contains oily constituents, water, an emulsifying agent and an osmotic pressure regulator, wherein the lipid emulsion contains a metal ion chelant but not an antioxidant. The content of the metal ion chelant is below 100mg/ml. The metal ion chelant is one or more of sodium calcium edentate, edetate disodium, edetate sodium and edetic acid. The invention relates to a method for preparing the lipid emulsion with the low anisidine value as well. According to the invention, in the process of preparing the lipid emulsion, other antioxidants are not needed to add, such as Vitamin E (VE), the antioxidation can be implemented only by using the metal ion chelant, and the low anisidine value can be greatly reduced. The low anisidine value of the lipid emulsion cannot be reduced by adding other antioxidants.
Capsaicin cream, which stimulates the TRPV1 (transient receptor potential vanilloid 1) receptor, causing a burning sensation, will be applied to both halves of the upper lip until a burning sensation with 8/10 intensity on an NRS (Visual Analog Scale) scale is experienced or five minutes have elapsed. Following this, the capsaicin cream will be wiped off and 30% mannitol in vehicle cream ( isopropyl palmitate, caprylic capric triglyceride, propylene glycol, ceteareth 20, cetearyl alcohol, glyceryl stearate, polyethylene glycol 100 stearate, dimethicone, octyldodecanol, lecithin, ethylhexyl glycerin and phenoxy ethanol) will be applied to one half of the upper lip, and vehicle cream alone will be applied to the other half. Cream assignment will be randomized and neither the subject nor the person applying the cream will know which half upper lip has which cream. Every minute for 10 minutes, the heat sensation felt in each half upper lip will be measured, using a visual scale from 0 to 10. A repeated measures analysis of variance will compare the NRS (Visual Analog Scale) scores from the 30% mannitol cream, to the NRS (Visual Analog Scale)scores from the vehicle cream. Significance will be accepted if P less than .05.
This study will recruit from three experimental groups: (1)The DS (adult) group will consist of 15 DS subjects aged 21 and older who do not qualify for the diagnosis of dementia at the beginning of the study. (2)The DS/AD group will consist of 15 DS subjects aged 40 and older who do qualify for the diagnosis of dementia by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria. Diagnoses will be by standard consensus review of all cases. (3)Normal control (NC) adult will consist of 10 cognitively normal, non-DS individuals, age-matched to the DS group. Blood will be collected to assess apolipoprotein E (ApoE) genotype. Participation in the dried blood spot collection (DBSC) will be an optional sub-study. Only participants and/or their caregivers/legally authorized representatives indicating they wish to have DBSC performed on the consent will provide specimens.
Participants received an initial loading dose of trastuzumab 4 milligrams per kilogram (mg/kg), intravenously (IV), over 1.5 hours during Week 1, followed by 2 mg/kg, IV, over 30 minutes once per week from Week 2 to Week 52 or until disease progression. Participants also received myocet, 40 mg/ square meter (m\^2), IV, every 3 weeks, from Week 1; if no dose limiting toxicity (DLT) was observed in greater than or equal to (≥) two-thirds (2/3) of cohort for 2 treatment cycles, the dose was increased to 50 mg/m\^2, IV, and continued for 6 cycles. Participants also received paclitaxel 60 mg/ m\^2, IV, once per week, from Week 19; if no DLT was observed in ≥ 2/3 of cohort for 2 treatment cycles, the dose was increased to 70 mg/m\^2, IV, and subsequently 80 mg/m\^2, IV, and continued until disease progression.
Standard therapeutic arm. Placebo orally once a day continuously together with gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 7 consecutive weeks. This will then be followed by a one week break and then gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 3 weeks followed by a one week break in subsequent cycles.
The invention belongs to the technical field of Chinese herbal medicine preparations and preparation thereof, and discloses a preparation for treating liver-kidney yin deficiency and a preparation method thereof. The preparation is prepared by mixing various Chinese herbal medicines with abundant sources and proper drug effect. The Chinese medicinal preparation has the advantages that the compatibility of all medicinal materials is equivalent according to monarch, minister, assistant and guide, and the sheep liver powder is used as monarch drug, has the effects of nourishing liver, improving eyesight, clearing deficiency heat, generating blood, benefiting blood and enriching blood; lily and polygonatum are used as ministerial drugs for nourishing yin, clearing heat and nourishing essence and blood; radix Stemonae is used as adjuvant drug to warm middle energizer and eliminate dampness, relieve cough and reduce sputum; the liquorice is used as a guiding drug to coordinate the effects of the various drugs, tonify and regulate the middle warmer and alleviate the drug property. The medicines are combined to achieve the effects of clearing deficiency and nourishing yin, nourishing and benefiting blood, warming spleen and stomach and eliminating dampness. Under the effective cooperation of various medicinal materials, the symptoms of dizziness, anemia, hypodynamia and drug-induced liver and kidney hypofunction of patients with severe diseases are promoted to be cured. The preparation method of the preparation has simple operation process. The Chinese medicinal preparation is safe and reliable, has no irritation, no toxic or side effect, and is suitable for individuals of all ages.
Taking a fragment of colon tumors taken from a specimen. Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
PROBLEM TO BE SOLVED: To provide pharmaceutical compositions with phosphonium antimicrobial agents.SOLUTION: The present invention is related to pharmaceutical compositions that include a phosphonium antimicrobial agent. In a preferred embodiment, the present invention relates to an otic, nasal or ophthalmic composition (e.g., an aqueous ophthalmic solution) that includes a phosphonium salt compound as an antimicrobial agent. The compositions typically possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements and/or similar preservative standards (e.g., EP and JP). The present invention is predicated upon the provision of a pharmaceutical composition that includes a phosphonium compound as an antimicrobial agent. Advantageously, it has been found that such compositions can be formulated to exhibit relatively high degrees of anti-microbial activity while also exhibiting relatively low toxicity. Such phosphonium compounds have been found to be particularly useful as antimicrobial agents in ophthalmic compositions such as contact lens disinfecting solutions and ophthalmic pharmaceutical compositions (i.e., ophthalmic compositions includes an ophthalmic therapeutic agent).SELECTED DRAWING: None
This is a 16-week study with an 8-week meditation intervention, with a requirement of a minimum of 10 minutes of meditation practice each day. This study will recruit \~200 healthy subjects (18+ years) with no current or previous diagnosis of psychiatric or neurological disorders who are interested in learning about meditation but don't have long-term experience with meditation. Half of the participant pool will be randomly assigned to the meditation intervention, and the other half will get the wait-list control assignment. The control group will later receive its intervention, likely a few weeks after the completion of the active group's intervention. A focused-attention meditation technique (SOS meditation) will be used to train participants.

Changes in participants' physiological markers (e.g., HRV, physical activity, respiration rate, sleep quality) will be evaluated using passive activity monitoring devices (e.g., Fitbit). Intervention-related changes in mental health will be assessed using web-based mental health and well-being surveys. Improvements in cognitive functioning will be assessed using web-based psychological tasks.
Medicament for topical treatment of epidermic proliferation cancerous tumours contains 5-methoxy psoralen, (I), in concentrations of 1000-10,000 ppm, with a suitable vehicle. The compsns. pref. contain a penetration agent, such as dimethylsulphoxide (DMSO). Medicaments for oral treatment of pre-cancerous or cancerous tumours contain (I) in doses of 200-400 mg. (I) is a known cpd. (see FR applications 77.31719) which may be applied topically, at concentrations of 100-1000 ppm, for the treatment of psoriasis, vitiligo, atypic eczema and fungoid mycosis. pref. in association with UV irradiation, and may be administered orally in daily doses of 20-300 mg. Epidermic cell proliferation tumours, such as baso-cellular epithelioma, spino-cellular epithelioma, Hutchinson reddening actinic hyperkeratosis, cutaneous melanoma etc. are caused by solar irradiation and the above treatment was considered unsuitable. The present invention uses 10-100 times higher concentrations of (I) to treat these tumours topically. (I) is well tolerated at these high concentrations. Clinical tests show that (I) can be administered orally, in daily doses of 400-800 mg/kg and gives good results with no toxicity problems.
Development of high-sensitivity assays for cardiac troponin I (hs-TnI) has enhanced the ability to detect low circulating levels of cardiac troponins, which are often present in individuals with common cardiac conditions and risk factors who have not manifested clinical cardiovascular disease (CVD). Lowering the detection threshold of troponin assays has expanded the potential use of cardiac troponins from a diagnostic tool in the setting of acute coronary syndrome to a biomarker for risk stratification in individuals without known CVD. Detectable levels of cardiac troponins have been associated with increased incidence of coronary heart disease (CHD), heart failure (HF), and cardiovascular mortality in community-based studies.

Traditional cardiovascular risk prediction does not identify everyone who will develop cardiovascular disease with up to 50% of individuals having none or only one risk factor at the time of diagnosis. Although traditional risk estimations perform moderately well, there remain significant limitations in their use in the prevention of cardiovascular disease especially at an individual level. At an individual level, the clinician not only needs to correctly identify those at increased risk, but also weigh up the importance of each risk factor and determine who needs medical therapy in addition to lifestyle advice Many risk estimation systems in existence are based on a core set of cardiovascular risk factors and based on participants either selected randomly from the general population or those attending their general practitioner. All these risk scoring systems show a good level of discrimination, for cardiovascular events, with the area under the receiving operator curve ranging from 0.73 to 0.82. However, adopting these risk scoring systems to guide current clinical practice has limitations. First, most of these scoring systems, except QRISK1 and QRISK2 have been developed from old prospective cohorts with participants recruited in the 1980's and 1990's Second, applying risk estimation scores to regions with different rates of baseline rates of cardiovascular disease will lead to either under- or over-estimation of risk: a result of mis-calibration. Third, the value of incorporating new risk factors including biomarkers such as high-sensitivity C reactive protein has been disappointing in improving discrimination, with age and sex alone contributing to 0.70 of the area under the receiver operating curve statistic. None of these risk estimation scores, to date, incorporate a direct measure of cardiac injury such as cardiac troponin and its potential role in guiding primary prevention in a contemporaneous population remains uncertain.
Optimune is an web-based psychological intervention for women with breast cancer. Beyond established CBT techniques targeting depression, anxiety, and fatigue, this intervention specifically includes elements that have shown effects on markers of immune status and inflammation, including sleep, stress management (e.g., mindfulness-based techniques) and lifestyle optimization (dietary and physical activity advice). Content is continuously adapted to users' concerns and needs. It contains interactive dialogues that can be accessed via computer or smart-phone, illustrations, audio files and motivating text messages. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.
NEW MATERIAL:A compound of formula I (R is hydrophobic acyl; l, m, p and q are each 2-4; n is 0-2). EXAMPLE:2,4-Dioxo-3-(l-naphthylacetylamino)l,5,8,12-tetrazacyclotetrad ecane. USE:A glutamic acid receptor blocking agent. Useful as a therapeutic medicine for neurotransmission inhibition and encephalopathy. PREPARATION:The objective compound of the formula I can be obtained by condensation reaction between a cyclic amine of formula 3 and a carboxylic acid of formula 4. For said reaction, a conventional amide linkage formation process (for example, a carboxylic acid is made into its acid chloride) can be used. The molar ratio of the compound of the formula 3 to the compound of the formula 4 is pref. >1.
Participants with moderate renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein.
Paraesophageal hernias are hernias in which the stomach and/or other abdominal organs herniate through the diaphragm into the chest. This abnormal anatomy can lead to acid reflux, trouble swallowing, and shortness of breath, and can also be a risk factor for surgical emergencies involving the stomach. For these reasons, the Society of American Gastrointestinal and Endoscopic Surgeons has strongly recommended that all symptomatic paraesophageal hernias be repaired.

These repairs are technically challenging, and the best available evidence suggests that more than half of patients undergoing repair will have radiographic hernia recurrence at 5 years after surgery. There has been suggestion that use of anterior gastropexy - in which suture is used to affix the stomach to the anterior abdomen - may reduce recurrence rates. However, it is uncertain whether this data is reliable. While some surgeons use anterior gastropexy routinely because they believe it reduces recurrence, other surgeons do not use anterior gastropexy due to the concern that patients will have short-term pain at the suture site. This study aims to evaluate the effect of using anterior gastropexy on recurrence rates after paraesophageal hernia repair, compared to not using anterior gastropexy.
Objectives of study are to determine activity of combo of Irinotecan + Temozolomide \& to further characterize any toxicity associated w combo of Irinotecan + Temozolomide. Temozolomide administered orally at 200mg/m2 in fasting state 1hr prior to CPT-11 infusion. Temozolomide administered on day 1 of treatment cycle \& every 24hrs thereafter for 5 days w treatment cycles repeated every 6wks. Treatment cycles may be repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. At end of 3rd cycle/if cycles are stopped early for toxicity or progression, subject will undergo radiation therapy. CPT-11 administered intravenously in fasting state over 90min. CPT-11 will begin 1hr after Temozolomide administration on day 1 of treatment cycle. CPT-11 administered on days 1, 8, 22, \& 29 of 6wk treatment cycle. Treatment cycles may be repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. Dose of CPT-11 will be based on whether pt is receiving CYP3A4-inducing antiepileptic drugs due to increased drug clearance produced by these agents. For pts receiving EIAEDs including phenytoin, fosphenytoin, oxcarbazepine, phenobarbital/ primidone, CPT-11 dose of 325mg/m2 administered. For pts not receiving EIAEDs, CPT-11 dose of125 mg/m2 administered.

Subjects have newly diagnosed histologically proven supratentorial glioblastoma multiforme. Toxicities associated w CPT-11 are anemia, decreased blood counts, diarrhea, constipation, nausea, vomiting, tiredness, fever, mouth sores, dehydration, rash, itching, changes in skin color, swelling, numbness, tingling, dizziness, confusion, low blood pressure, sweating, hot flashes, hair loss, inflammation of liver, flu-like symptoms, decreased urine output, shortness of breath,\& pneumonia. Low white blood cell \& platelet counts may be associated w risk of infection/bleeding, respectively. Irinotecan has also caused birth defects in animals. Most frequent toxicities in earlier studies have been low white blood cells \& diarrhea, \& death has been seen from these \& other side effects. Temozolomide has been well tolerated by both adults \& children w most common toxicity being mild myelosuppression. Other, less likely, potential toxicities include nausea \& vomiting, constipation, headache, alopecia, rash, burning sensation of skin, esophagitis, pain, diarrhea, lethargy, hepatotoxicity, anorexia, fatigue \& hyperglycemia. Hypersensitivity reactions have not yet been noted w Temozolomide. As in case w many anti-cancer drugs, Temozolomide may be carcinogenic.